The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Many cities in Europe are known for their beauty, history and culture. However, one city…
Tripura, a beautiful state in northeastern India, has a growing railway network that connects it…
The Union Cabinet on 12th December, 2025 has approved a major update to India’s largest…
There is a beautiful hill station in the Kumaon region of Uttarakhand, India, known for…
Some countries are famous for their mountains, deserts or forests, while others are known for…
The Union Cabinet Committee on Economic Affairs has approved a major new policy called CoalSETU…